2025-10-14 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA), incorporating all the provided data points.

**Report on Natera Inc. (NTRA)**

**0) Introduction:**

This report analyzes Natera Inc. (NTRA), focusing on its stock performance, financial health, recent news, and analyst opinions. The analysis includes a comparison with the S&P 500 (VOO), technical indicators, and earnings data.

**1) Performance Overview & Comparative Analysis:**

*   **Ticker:** NTRA
*   **Company Description:** Natera Inc. is a diagnostics company specializing in cell-free DNA testing.
*   **NTRA Cumulative Return:** 80.03%
*   **VOO (S&P 500) Cumulative Return:** 96.94%
*   **Return Disparity:**
    *   Current Disparity: -23.4
    *   Max Disparity: 174.8
    *   Min Disparity: -88.5
    *   Relative Disparity: 24.7

**Return Disparity Analysis:** NTRA has underperformed the S&P 500 by 16.91% in cumulative return. The relative disparity of 24.7 indicates that NTRA is currently positioned in the lower end of its historical performance range relative to the S&P 500.

**Alpha, Beta, and Performance Metrics:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | -10.0%  | 70.1%   | -34.0%  | -0.2   | 1.2    |
| 2016-2018  | 22.0%   | 80.0%   | 6.0%    | 0.1    | 1.9    |
| 2017-2019  | 50.0%   | 80.0%   | 28.0%   | 1.0    | 4.6    |
| 2018-2020  | 186.0%  | 80.5%   | 163.0%  | 1.1    | 13.7   |
| 2019-2021  | 96.0%   | 80.5%   | 49.0%   | 1.6    | 12.8   |
| 2020-2022  | -77.0%  | 80.5%   | -76.0%  | 0.1    | 5.5    |
| 2021-2023  | -194.0% | 76.6%   | -195.0% | -1.1   | 8.6    |
| 2022-2024  | 8.0%    | 76.6%   | -13.0%  | -1.2   | 21.7   |
| 2023-2025  | 107.0%  | 76.6%   | 46.0%   | 0.1    | 23.9   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** The CAGR shows significant volatility, with periods of high growth (e.g., 2018-2020) and substantial losses (e.g., 2021-2023).
*   **MDD (Maximum Drawdown):** High MDD values consistently indicate significant risk and volatility.
*   **Alpha:** Alpha fluctuates widely, suggesting inconsistent outperformance relative to the benchmark. Negative alpha values indicate underperformance.
*   **Beta:** Beta values vary, indicating that NTRA's correlation with the market changes over time. A beta greater than 1 suggests higher volatility than the market.

**2) Recent Stock Price Movement:**

*   **Current Price:** $174.17
*   **Previous Close:** $169.27
*   **Change:** $2.89
*   **5-Day Moving Average:** 170.864
*   **20-Day Moving Average:** 169.208
*   **60-Day Moving Average:** 160.0926

**Analysis:** The current price is above all three moving averages (5, 20, and 60 days), suggesting a short-term upward trend. The notable price change ($2.89) indicates a positive momentum.

**3) Technical Indicators & Outlook:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 59.84 (Approaching overbought territory but still neutral)
*   **PPO:** 0.2292 (Positive, indicating an upward trend but still low)
*   **Hybrid Signal:** Buy 100% of cash (6 shares - Very Safe - MRI:0.90)
*   **20-Day Relative Disparity Change:** 3.7 (+) (Short-term increase, indicating recent outperformance)
*   **Expected Return:** -143.9% (Long-term underperformance relative to S&P 500)

**Analysis:** The MRI suggests a medium level of investment risk. The RSI is neutral, while the PPO signals a minor upward trend. The hybrid signal recommends a buy based on safety and MRI score. The negative expected return indicates potential long-term underperformance.

**4) Recent News & Significant Events (Yahoo Finance):**

*   **[2025-10-13]** The Bull Case For Natera (NTRA) Could Change Following Breakthrough Study Results for Signatera Platform (Simply Wall St.)
*   **[2025-10-13]** Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer (Insider Monkey)
*   **[2025-10-13]** Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings (Business Wire)
*   **[2025-10-13]** Natera (NTRA) Valuation: Exploring Upside as Investors Weigh Recent Performance and Long-Term Potential (Simply Wall St.)
*   **[2025-10-12]** Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium (Business Wire)

**Analysis:** Recent news highlights the positive potential of Natera's Signatera platform and its validation in testicular cancer. The upcoming investor call and ESMO presentations could be catalysts for future stock movement. The news also reflects optimism about the company's valuation and long-term potential.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.53 (~Buy)
*   **Opinions:** 19
*   **Target Price:**
    *   Average: 193.21
    *   High: 235.00
    *   Low: 37.00
*   **Recent Rating Changes:** No changes indicated.

**Analysis:** The strong buy consensus and high average target price suggest that analysts are optimistic about Natera's future performance. However, the wide range between the high and low target prices reflects uncertainty among analysts.

**5) Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-08-08 | -0.74 | 0.55 B$      |
| 2025-05-09 | -0.50 | 0.50 B$      |
| 2024-11-12 | -0.26 | 0.44 B$      |
| 2024-08-09 | -0.30 | 0.41 B$      |
| 2025-08-08 | -0.30 | 0.41 B$      |

**Analysis:** Natera has consistently reported negative EPS, but revenue has been growing. This suggests the company is investing in growth but is not yet profitable.

**6) Financial Information:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |
| 2024-06-30 | $0.41B  | 58.83%        |

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $1.25B  | -8.10%  |
| 2025-03-31 | $1.24B  | -5.40%  |
| 2024-12-31 | $1.20B  | -4.50%  |
| 2024-09-30 | $0.88B  | -3.60%  |
| 2024-06-30 | $0.84B  | -4.48%  |

**Analysis:** Revenue is increasing consistently, and the profit margin is high and improving. However, the Return on Equity (ROE) is negative, reflecting the company's current unprofitability. Equity has been growing, which is a positive sign.

**7) Summary:**

Natera Inc. (NTRA) is a diagnostics company with strong revenue growth and high profit margins, but it is currently unprofitable, with negative EPS and ROE. It has underperformed the S&P 500 recently, but positive news regarding its Signatera platform and optimistic analyst opinions suggest potential for future growth. Technical indicators are mixed, with a buy signal from the hybrid strategy and medium-risk indication from the MRI. Investors should carefully consider Natera's growth potential, profitability challenges, and market volatility before making investment decisions.
